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Summary.-Griseofulvin, an antibiotic used to treat dermatophytosis, was tested
for carcinogenicity in mice, rats and hamsters. Three groups of mice and rats were
given the drug in powdered diet in alternating 5-week periods for life, at dose levels
of 3.000, 1-500 and 0-300 (mice) and 2.0%, 1-0% and 0-2% (rats). A group of mice and
3 groups of hamsters received continuous daily treatment for life with griseofulvin
at 3-000, 1.5%, 0.300 and 0.1% dose levels respectively. A significant incidence of
hepatic tumours was observed at the 2 higher treatment levels in mice. Also, statis-
tically significant rates (P < 0.001 and/or P < 0.020) of thyroid tumours, indicating
a dose-response, were recorded in male rats at the2.00/ 1-0%0, and 0 2% dose levels,
and in females at the 2.0°, and 1.0% dose levels. Hamsters did not develop neo-
plasms in response to treatment at any level.
GRISEOFULVIN (Fulvicin grisactin), an
antibiotic derivative ofpenicillium moulds,
was first isolated from Penicillium griseo-
fulviarnt (Oxford et al., 1939). Structurally,
the compound is 7-chloro-2'4,6-trimeth-
oxy-6'-methylspirobenzofuran-2(3H), 1'-
[2]cyclohexene-3,4'-dione (Fig. 1). It has
been used extensively as an antifungal
agent to treat superficial dermatomycoses
in humans (Anderson, 1965; Beare et al.,
1968; Blank et al., 1959) and animals
(Beare et al., 1968; Blank et al., 1959).
Griseofulvin has also been successfully
used in World Health Organization-
sponsored mass treatment campaigns for
tinea capitis (Anonymous [WHO], 1966;
Grin, 1965) and in field trials for pro-
phylaxis of superficial dermatophytoses
(Ballo and Cutting, 1970). Although the
drug is valuable in controlling superficial
infection and, in general, causes no
notable side effects, there have been
reports in humans of transitory leuco-
penia, granulocytopenia (Blank et al.,
1959), acute intermittent porphyria (Eales,
1963; Redeker et al., 1964) and increased
faecal and erythrocytic protoporphyrin
at normal therapeutic dose levels (Blank
et al., 1959; Rimington et al., 1963).
In biological experiments, the com-
pound has induced mitotic arrest at the
metaphase stage (DeMatteis, 1963; Paget
and Walpole, 1958, 1960) and potentiated
the toxic effects of colchicine (Epstein and
Larson, 1961). Griseofulvin has produced
teratogenic effects in the rat (Klein and
Beall, 1972) and cat (Anon. [WHO], 1966),
with multiple malformations observed in
cat offspring at therapeutic doses (Scott
et al., 1975). Prolonged oral administra-
tion of griseofulvin to mice at elevated
doses severely impaired hepatic porphyrin
metabolism and caused hepatomegaly
(DeMatteis, 1963; DeMatteis et al., 1966;
Lochhead et al., 1967), extensive liver
damage (Barich et al., 1961; Hurst and
Paget, 1963) and hepatoma induction
(DeMatteis et al., 1966; Hurst and Paget,
1963). Hepatoma induction by griseo-
fulvin was also reported after s.c. admini-
stration of milligram quantities to infant
mice (Epstein et al., 1967). A cocarcino-
genic effect on skin-tumour development
in mice was noted when griseofulvin wasM. RUSTIA AND P. SHUBIK
OCH3 01 OCH3
0
C1 CH3
Fia. 1. Structure ofgriseofulvin (7-chloro-2',
4,6-tri-methoxy-6'-methylspirobenzofuran-
2-(3H),1'-[2]cyclohexene-3,4'-dione).
administered orally before, during, or
after topical treatment with methylehol-
anthrene (Barich and Barich, 1963; Barich
et al., 1960; Barich et al., 1962).
In this report we present findings from
carcinogenicity studies in mice, rats, and
hamsters treated for various periods with
griseofulvin.
METHODS AND MATERIALS
Animals.-Swiss mice (480), MRC-Wistar
rats (380) and Syrian hamsters (278), all
bred in the Eppley Colony, were housed in
plastic cages on San-i-cel beddingf (Anderson
Laboratory, Maumee, Ohio) and randomly
distributed by sex in groups of 6-7 (mice and
hamsters) or 5 (rats). Experimental and
control animals were inspected and weighed
weekly. Animals were allowed to die spontan-
eously or killed when moribund. Complete
necropsies were performed on all control and
experinmental animals, except for a few that
were cannibalized or displayed advanced
postmortem deterioration. Histological speci-
mens were taken from all tumours, lungs,
liver, spleen, kidneys, lymph nodes, pituitary,
adrenal and thyroid glands, pancreas, and
sternal marrow. Sections were also prepared
from other selected organs, and from all
pathologically altered tissue. Tissue was
fixed in 10% buffered formalin, processed
and stained routinely with haematoxylin
and eosin oi. with Van Giesen's, Gomori's,
periodic acid-Schiff or Masson's stains.
Test substance.-Micro-sized griseofulvin
(Schering Corporation, Lafayette, N.J.), pro-
cessed Rockland (A. E. Stanley Mfg. Co.,
Decatur, Ill). and Wayne Lab-Blox diets
(Allied Mills, Inc., Chicago, Ill.) were used.
The griseofulvin was incorporated into the
food with a roller-type Versa-Mill (Fisher
Scientific Co., Fair Lawn, N.J.).
Treatment
Mice.-Mice were divided into 4 groups
and given ad libitum food containing griseo-
fulvin. Groups 1-3 (Table I) received griseo-
fulvin daily for alternating 5-week periods
(5 weeks on treatment, 5 weeks offtreatment)
for life at the following doses: Group 1, 300/;
Group 2, 1-5% and Group 3, 0-3%. Group 4
received 0-10/ griseofulvin in food daily for
life. Groups 1 and 3 consisted of 30 males
and 30 females, and Groups 2 and 4 of 40
males and 40 females. Untreated controls
(Group 5, 100 males, 100 females) received
normal pelleted diet only.
Rats-.Three experimental groups (30
males and 30 females each) received griseo-
fulvin in the diet during alternate 5-week
periods for life (Table 1) at levels of: Group 1,
2%o; Group 2, 100 and Group 3, 0-2°.
Untreated controls (Group 4, 100 females
and 100 males) were maintained on normal
pelleted diet.
Hamsters. Three groups of hamsters re-
ceived griseofulvin in the diet daily for life.
Groups of 30 males and 30 females were
treated as follows: Group 1, 300; Group 2,
1.500 and Group 3, 0.3%o. The controls
(Group 4, 49 females, 49 males) received
normal pelleted diet.
Data on rats were analysed statistically by
the chi-square test and the standard t test.
RESULTS
Mice
Treatment and survival rates are given
in Table I. In the initial 2 weeks of the
experiment, mice tolerated the drug well,
and exhibited no signs of toxic effect.
Thereafter, however, mice had distended
abdomens, showed an apparent somno-
lence and jaundice (icterus). Many animals
at the upper 3 dose levels died during the
first 5 weeks of the experiment, with most
deaths occurring in Group 1 males (30o
dose level). Treatment was then interrup-
ted for 5 weeks in Groups 1-3, while the
animals recuperated, they then received
griseofulvin in their food for alternate
5-week periods throughout their life. In
Group 4, daily treatment continued un-
interrupted. The livers were seen at
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TABLE I.- Survival in rats, mice and hamsters
Survival (weeks)
10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160
30
30
29
30
30
30
100
100
24
18
28
28
26
24
40
34
91
95
29
30
29
30
28
30
47
45
30
30
29
30
30
30
100
98
24
18
26
27
25
24
37
33
89
90
28
30
28
29
27
26
35
45
30 30 30 30 28
30 30 29 28 26
29 29 29 29 27
30 30 30 30 29
30 30 30 29 29
30 29 29 29 27
100 99 99 97 94
97 93 90 82 64
22 21 21 10 3
17 14 12 8 3
26 26 19 15 6
27 26 20 17 9
25 23 23 18 15
24 22 22 16 8
37 36 33 24 17
32 30 26 17 9
85 76 68 54 34
79 69 49 36 15
22 17 12 5 1
27 26 24 21 18
24 16 8 5 2
28 25 23 16 10
21 16 14 9 2
22 20 16 11 6
29 23 22 16 10
40 33 22 16 14
24
23
27
29
28
23
87
44
0
0
1
0
12
4
10
4
14
8
0
13
0
8
1
4
0
12
22
20
25
28
25
22
74
27
0
0
0
0
5
2
3
2
6
4
0
8
0
3
0
2
0
7
20
16
22
24
20
16
55
11
0
0
0
0
0
0
0
0
3
4
0
2
0
1
0
0
0
0
18
12
17
18
17
11
30
3
14
7
16
8
16
7
11
0
9
7
10
1
10
4
0
0
4
1
2
1
6
1
0
0
* In diet (laily for: rats, alternate 5-week periods for life (Groups 1-3); mice, alternate 5-week periods for
life (Groups 1-3) or daily for life (Group 4); hamsters, daily for life (Groups 1-3).
t All animals were 7 weeks old at start.
necropsy to be enlarged, friable and green-
ish-brown in colour.
On histological examination the hepatic
tissue showed severe damage, character-
ized by accumulation ofgolden-brown pig-
ment, necrosis, bile-duct proliferation,
intraductal hyperplasia, fibrosis and areas
of atypical hepatocytes with cytoplasmic
and nuclear irregularities. Golden-brown
granular pigment occurred in hepato-
cytes, Kupffer cells, original bile ducts and
in the numerous newly proliferated bile
ducts. Pigment extensively increased,
mostly in the dilated bile ducts, and
formed extensive, dark-brown plugs that
obstructed biliary passages, particularly in
Groups 1 and 2 at advanced stages of the
experiment. Pigment deposits in the
Kupifer cells were also increased. Fre-
quently, conglomerates of these cells
within the liver sinusoids and portal
tracts formed giant cells that stored vast
quantities of pigment. Although moderate
amounts of pigment were detected in
normal parenchymal liver cells, hepato-
cytes and hepatomas were consistently
devoid of this material. The brown pig-
ment was associated with varying degrees
of inflammation, consisting of lympho-
cytes, histiocytes and increased connect-
ive tissue. The new bile ducts extended
from the portal tracts, and penetrated
between the columns of hepatocytes. In
other areas, large zonesofliverparenchyma
were destroyed by proliferating, dilated
bile ducts. A marked intraductal biliary
hyperplasia, which sometimes acquired
adenomatoid characteristics was frequent-
ly noted in Groups 1 and 2.
Hepatomas. The incidence and average
30 30
30 30
30 30
30 30
30 30
30 30
100 100
100 100
Treatment
% griseo-
fulvin in
food*
2-0
1 0
0-2
Controls
3 0
1 -5
0 3
0-1
Controls
3 0
1 -5
0 3
Controls
Group No.
Rats:
1,
2
3
4
Mice:
1
2
3
4
5
Hamsters:
1
2
3
4
Initial
No. of
animals,
sext
30, S
30, S
30, d
30, V
30, J
100, V
100, d
30, $
30,
40, S
40, s
30, 9
30, c;
40, C
100,3
100, V
30, X
30, 9
30, c
30, 9
30,
30, 9
49, 9
49, c;
30
30
40
40
30
30
40
40
99
100
30
30
30
30
30
30
48
46
24
18
28
28
27
24
40
36
98
97
30
30
29
30
29
30
48
45
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FIG. 2.-Hepatoma, well-differentiated. Note enlarged cells within tumour and compression of surround-
ing liver parenchyma. Male mouse, 75 weeks old. H & E. x 90.
FIG. 3.-Hepatoma. Note trabecular arrangement and intensive vacuolation within cytoplasm of tumour
cells. Male mouse, 82 weeks old. H & E. x 140.
FIG. 4.-Hepatoma, glandular type. Note formation of acini and deposit of fibrous tissue. Male mouse, 95
weeks old. H. & E. x 140.
FIG. 5.-Hepatoma, tra4ecular type. Note severe pleosnorphism and giant cell (centre). Female mouse, 87
weeks old. H. & E. x 140.
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latent periods of the hepatic tumours
are given in Table II. Group l and 2 males
and females developed a significant inci-
dence of hepatomas. Although Group 1
females had a higher percentage of hepa-
tomas than did males (87% vs 8333%) and
Group 2 males had higher percentages of
these neoplasms than females (680o vs
536%), the differences between groups
and between the sexes were not significant.
Males in Groups 3 and 4 developed only
3 hepatomas (2, Group 3; 1, Group 4)
but no control animals had these
tumours.
Histologically, liver tumours were either
well-differentiated and solid with a struc-
ture similar to that ofnormal liver (Fig. 2),
less differentiated trabecular (Fig. 3) or
(occasionally) glandular (Fig. 4), in which
case the liver structure was completely
obliterated. The tumour cells in the well-
differentiated neoplasms were arranged
in 1-2 cell-thick plates similar to those of
the normal liver cords. The intervening
sinusoids were narrowed or obliterated
because of expanding large neoplastic
cells. However, in some areas, particularly
in the central portions of large nodules,
tumour cells were arrang,ed in small clus-
ters and separated by wide sinusoidal
spaces often containing large quantities
of blood. The surrounding parenchyma
was commonly compressed (Fig. 2) owing
to the expansive growth of these tumours.
The transition from tumour to the sur-
rounding normal hepatic tissue was some-
times poorly defined. The less-differentia-
ted, trabecular-type tumours consisted of
irregular cords several cells thick, and were
divided by wide (sometimes narrow) vas-
cular spaces. Occasionally the glandular
type of tumour formed acini (Fig. 4) in
association with extensive fibrosis.
Cytological irregularities included con-
spicuous hyalin and refractile eosinophilic
inclusion bodies, intranuclear eosinophilic
inclusion bodies, vacuolization of cyto-
plasm (Fig. 3), frequent basophilia, some-
times extensive pleomorphism and aniso-
karyosis (Fig. 5). These cytological fea-
tures were more apparent in the less-
differentiated neoplasms. No extra-hepatic
metastases were noted.
Other tumours.-There was no signifi-
cant difference in incidence of tumours
other than hepatocellular neoplasms, be-
tween treated and control mice. Although
there was an increased percentage of lung
tumours among Group 3 males (28 0% vs
16.3% in controls) and of malignant
lymphomas among Group 3 females
(35.70% vs 27.6%), the increase in both
tumour types was not significant.
Rats
Table I gives treatment and survival
rates for test and control rats. In the first
3 weeks of the experiment, the rats
tolerated the drug well, but thereafter dis-
played such signs of toxic effect as
somnolence, sometimes slight icterus, and
abdominal distention. Toxic effects, al-
though more prominent in male rats,
were less intense than in mice, since no
animals died within the first 10 weeks of
the experiment. Livers showed traces of
golden-brown pigment (probably proto-
porphyrin) in the Kupffer cells, and a
virtual absence of such material in liver
parenchymal cells.
Thyroid tumours.-The frequency and
percentage of tumours are given in Table
III. The incidence of thyroid tumours in
Group 1 males (53.30o) and females
(2333%) was highly significant (P <- 0-001)
when compared with the spontaneous
incidence in controls (10% for males and
2% for females). Group 2 rats developed
fewer thyroid tumours (36.7%o) and fe-
males 26 7%, which was still significant
for both sexes (P < 0'001). The percentage
of thyroid tumours in Group 3 was con-
siderably lower [13.3% in males, statisti-
cally significant (P <0 02), and 6-7% in
females]. The ratios of thyroid tumours at
the 3 consecutive dose levels indicated a
classic dose-response relationship. Grossly,
the thyroid tumours varied in size and
shape. Large nodules associated with
enlargement of the entire lobe were rare.
Macroscopically, nodules ranged from
3-10 mm in diameter and appeared well-
243244 M. RUSTIA AND P. SHUBIK
0
>
rn
0 o o No(o
Ig 0to * - * - °
_ o C0 Ono t o m
O r
0 1(=
C;~~~ . . X .
£, , o > F) o C_
02 lt o C9 c)
I m c t
O r
O * in .0 . . .
CaH o' c0 o C nn
Ca "D 00 .-I - _ _
O<F (:F C >
cs Icoobr e _
*H in 0o C * b *
* ~ ~ ~
.O ; ,O O
011 e'-
c)
E \ otlO O 40 o-4 ot' fo
4a; 000 0 00C co 0
c)a
6-o 0W0
-_ c0 It
0
o .) a)
ni
.
V
V .
bO
.2.
0
. .. o .
V .
..-
ni
V .
0
0
V
V
I.
0 02 9
- 6 14 . .
- -.4 e, P. u g. pq ;,. 0 0., 4-.' g U2 0 . ICa bo
ACARCINOGENICITY TESTS WITH GRISEOFULVIN 245
A
I.
7)
(8.
FIG. 6. Adenoma, follicular type, of thyroid gland. Note hyperplastic epithelium, abundance of colloid in
macrofollicular and occasional psammoma bodies. H. & E. x 80.
FIG. 7.-Adenoma, micro- and macrofollicular pattern of architecture. Note dense areas ofneoplastic tissue
and compression of normal follicles at right. H. & E. x 80.
FIG. 8. Carcinoma of thyroid, papillary type; neoplastic tissue exhibiting both follicular and papillary
structural arrangement. Note short papillary structure into cystic cavitation. H. & E. x 160.
FIG. 9. Carcinoma of thyroid, follicular type. Note few microfollicular structures and massive invasion of
neoplastic tissue in fibrous capsules (arrow). H. & E. x 100.
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circumscribed. Histologically, the thyroid
tumours were predominantly adenomas,
consisting of follicles, which were either
of macrofollicular (Fig. 6) or macro- and
microfollicular types (Fig. 7) and/or of
papillary-cystic structures. Since many
thyroid adenomas had features of both
types of neoplasm, they could be termed
mixed thyroid adenomas. The colloid
material was usually abundant in macro-
follicles and cysts, but appeared scarce or
absent in the microfollicles. The follicular
epithelium of thyroid tumours was cuboi-
dal and uniform in shape, but more
flattened in macrofollicles and cysts. Most
thyroid-tumour-bearing animals had cys-
tic cavitations containing various amounts
of colloid material within the lesions (in
over 70% of all cases). In numerous
instances, solitary cysts with colloidal
material were found in the thyroid glands
of non-tumour-bearing animals. It would
appear that the drug exerted some goi-
trogenic effect on the thyroid.
Thyroid carcinomas with varying
degrees of anaplasia were of either papil-
lary or follicular types. Some of the car-
cinomas had distinct papillary projections
into the cystic spaces (Fig. 8) and con-
tained sparse amounts of colloidal mat-
erial. The follicular type of carcinoma was
characterized by small follicles lined by
cells having dense nuclei with coarse
chromatin. The microfollicles were usually
devoid of colloidal material. Carcinomas
had thick capsules invaded by neoplastic
cells (Fig. 9). No distant metastases of
thyroid tumours were found. There were
4 carcinomas (in 3 males and 1 female) in
Group 1 and 3 (2 males and 1 female) in
Group 3. Three tumours in controls were
benign thyroid adenomas. One medullary
carcinoma of the thyroid deriving from
C cells was encountered in a thyroid-
adenoma-bearing animal.
Other tumours.-Table III lists other
tumours in rats. Group 2 animals had an
increased incidence of pituitary gland tu-
mours, predominantly in males, mammary
tumours in females, and interstitial-cell
tumours of the testes. A squamous-cell
tumour of the skin, and tumours of the
peripheral nervous system were present in
Group 1. Pituitary tumours were mainly
adenomas but there were a few carcino-
mas. Many of these tumours (over 50%)
were associated with thyroid-tumour-
bearing animals. Over 60% of the females
with mammary tumours had pituitary
adenomas, but the latter type occurred
at an even higher rate (70%) in controls.
The prevailing types of mammary tu-
mours were fibroadenomas, adeno-fibro-
mas and adenomas. Several mammary
tumours were adenocarcinomas, which
appeared in both control (5) and test (7)
groups. The parathyroid tumours in both
control and test animals were benign
adenomas. The incidence ofthese tumours
in Group 3 does not appear significantly
increased when compared with the para-
thyroid tumours occurring in controls.
The skin tumours in Group 1 males were 3
squamous-cell papillomas, one tricho-
epithelioma and 3 squamous-cell carcino-
mas, while controls had 6 squamous cell
papillomas and 1 squamous-cell carcinoma.
A number of other tumour types in test
and control rats (Table III) were repre-
sentative of lesions commonly found in
untreated Eppley rats.
Hamsters
The treatment and survival rates of
experimental and control hamsters are
given in Table III. Compared to mice and
rats, the hamsters tolerated griseofulvin
well, and showed no excessive toxic
effects.
The incidence oftumours, their distribu-
tion and origin showed no significant
differeiices between test and control ham-
sters. The tumour types by group (and
latency in weeks) are as follows: Group 1,
females-I fibrosarcoma of subcutis (52);
males-3 adenomas of adrenal cortex
(100, 116, 124), 1 adenocarcinoma of
thyroid (102), 1 sarcoma ofsubcutis (106),
1 malignant lymphoma, histiocytic type
(119); Group 2, females-I granulosa-cell
tumour of ovary (94); males-2 adenomas
of adrenal cortex (117, 120), 1 adenoma of
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kidney (99); Group 3, females 1 cholan-
giocarcinoma of liver (87), 1 granulosa-
theca-cell tumour of ovary (83), 1 adeno-
carcinoma ofuterus (10.1), 1 squamous cell
carcinoma of skin (87); males-malignant
lymphoma, histiocytic type (118); Group
4, females-2 papillomas of forestomach
(75, 88), 1 haemangioma of ovary (88),
1 squamous-cell carcinoma of uterus (99),
1 haemangioma ofliver (96), 1 haemangio-
ma of spleen (96), 1 adenocarcinoma of
uterus (99), 1 adenocarcinoma of adrenal
cortex (99), 1 carcinoma of thyroid (78),
1 myxosarcoma, retroperitoneal (92);
males-2 pheochromocytomas of adrenal
gland (116, 116), 2 malignant lymphomas,
histiocytic type (87, 100), 2 fibrosarcomas
of subcutis (76, 84), 1 papilloma of fore-
stomach (114), 1 adenoma of adrenal cor-
tex (1]05), 1 adenoma of gall bladder (84).
DISCUSSION
Dietary exposure to griseofulvin pro-
duced a significant incidence of hepato-
cellular tumours in mice, thyroid tumours
in rats, but no carcinogenic activity in
hamsters.
The total number of hepatomas was
particularly significant in mice fed at the
2 highest dose levels, while the rates of
hepatocellular tumours decreased propor-
tionately at lower concentrations, indicat-
ing a dose response for the incidence of
neoplasms in experimental groups. The
hepatocarcinogenic effect of griseofulvin
and the manifestation of a dose response
were reported by Hurst and Paget (1963)
who used only 2 dose levels. Subsequently,
De Matteis et al. (1966) found a pro-
nounced sex difference in the hepatocellu-
lar tumour incidence of mice exposed to
griseofulvin, in that males not only showed
a greater incidence and multiplicity of
these tumours, but also a higher degree of
porphyria and more pronounced histo-
logical changes in liver. Similarly, hepatic-
cell tumours have occurred in male mice
exposed to milligram quantities of griseo-
fulvin at birth and infancy (Epstein et al.
1967). The exclusive hepatocarcinogenic
effects of griseofulvin in mice in the pre-
sent experiment are consistent with results
in different strains of adult mice (De-
Matteis etal., 1966; HurstandPaget, 1963),
and with those of Epstein et al. (1967)
in newborn or infant mice. At variance
with previous reports (DeMatteis et al.,
1966; Epstein et al., 1967) is the produc-
tion in the present experiment of hepato-
cellular tumours in both female and male
mice.
Little is known of the mechanisms by
which griseofulvin is hepatocarcinogenic
in mice. Hurst and Paget (1963) suggested
that massive deposits of protoporphyrin
in finer ramifications of the biliary tract
caused biliary cirrhosis, an alteration that
could result in neoplasia. However, the
strong hepatocarcinogenic effect of the
drug in infant mice dosed briefly parent-
erally (Epstein et al., 1967) indicates an
involvement of griseofulvin with cellular
constituents (nucleic acids or proteins).
Recently it was suggested that hepato-
ma induction in mice cannot be held as a
valid demonstration of carcinogenicity
(Grasso and Crampton, 1972). Tomatis
et al. (1973), however, indicated that
induction of liver-cell tumours in mice
should be considered as valid a demonstra-
tion of carcinogenicity as tumour induc-
tion in rats and hamsters.
The finding of thyroid tumours in rats
is especially interesting, because in pre-
vious studies (Paget and Walpole, 1960;
Paget and Alcock, 1960) with this anti-
mitotic drug, no such tumours were
reported. These neoplasms have been
induced by irradiation (Lindsay et at.,
1961; Nichols et al., 1965; Lindsay et al.,
1968; Money et al., 1965), administration
of goitrogens (Money et al., 1965), and by
maintaining animals on an iodine-deficient
diet. The mechanism of genesis for these
tumours is unknown, but inourstudyover
70% of thyroid-tumour-bearing animals
had cystic dilatations containing colloid
material, which suggests a possible goitro-
genic effect. It is, of course, a matter of
speculation whether such an effect may
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be associated with tumour induction by
griseofulvin.
The carcinogenic activity ofgriseofulvin,
as corroborated in this experiment, was
formerly limited to mouse liver (DeMat-
teis et al., 1966; Lochhead et al., 1967).
While previous reports in rats (Klein and
Beall, 1972; Paget and Alcock, 1960) have
yielded little information about carcino-
genicity (perhaps owing to their brevity),
our study records positive results in this
species. However, further experimental
data in rats on the mechanism of induc-
tion of thyroid tumours and other neo-
plasms, including the use of other bio-
logical systems for carcinogenicity assay,
are required, as are epidemiological studies
in man.
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